NOVA Instagram NOVA Whatapps NOVA Fb Messenger NOVA Youtube NOVA eShop
Health Tips Img
29 Nov 2021

Hepar-P Positive Clinical Trial Results

Hepar-P Positive Clinical Trial Results
Hepar-P clinical trial results provide clear evidence on the safety and efficacy of Hepar-P in improving the liver stiffness (fibrosis) score and lowering elevated liver-specific enzyme ALT in patients with non-alcoholic fatty liver disease.

A Relentless Fight Against A Deadly Disease
Every year, millions of innocent lives die prematurely because of chronic liver disease. People suffering from obesity, high blood sugar, and high cholesterol levels are particularly at risk of developing chronic liver disease. Although it is a common disease, there are limited treatment options to help patients prevent the progression of chronic liver disease to an advanced stage, leading to a higher risk of liver cancer and premature death.

Phyllanthus niruri
Phyllanthus niruri has been widely used as a traditional medicine to improve liver health for over 3000 years. However, its safety and efficacy profile has not been established to promote its use in clinical settings.

Hence, we started the research on Phyllanthus niruri with the aim to conduct clinical trials to prove its safety and efficacy in improving liver health. We formulated Phyllanthus niruri as Hepar-P and commenced Hepar-P’s biggest clinical trial in 2018.

Hepar-P Clinical Trial
The clinical trial is designed to prove the safety and efficacy of Hepar-P in improving chronic liver disease, particularly non-alcoholic fatty liver disease - known to be the most common chronic liver disease that burdens our nation. This trial uses the gold standard research design to evaluate the safety and efficacy of Hepar-P for medical use, known as a multi-centred, randomised, placebo-controlled, double-blinded clinical trial.

Conducted by a team of medical specialists, this trial is carried out in 3 government hospitals – Hospital Sultanah Bahiyah Alor Setar, Hospital Ampang and Hospital Selayang. A total of 226 patients with non-alcoholic fatty liver disease (NAFLD) were recruited and randomly assigned to receive either Hepar-P or placebo.

At the end of the Hepar-P clinical trial, 3 positive results were observed:

  1. Safe for consumption up to 3000mg/day for 52 weeks.
  2. Effectively reduces the elevated liver-specific enzyme (ALT) and liver stiffness (fibrosis) score.
  3. Improvement in liver stiffness score can be seen as early as 3 months after using Hepar-P treatment.

This shows that Hepar-P can significantly improve liver functions in patients with non-alcoholic fatty liver disease and possesses protective effects against liver injuries by inhibiting lipid membrane oxidation, the root cause of chronic liver disease. With such positive results, we believe that Hepar-P will be a powerful tool in making our vision of a healthy liver world into reality and instil hope in patients with chronic liver disease.

This clinical trial underpins Nova’s core belief in providing evidence-based products supported by strong scientific evidence, and it is a part of Nova’s bigger mission to help everyone to improve their health and fight against chronic diseases.

For more details, visit this link:

Check out our Hepar-P Clinical Trial video:

Get Hepar-P now from your nearest pharmacy through our official online eShop

  1. Search for your nearest pharmacy
  2. Buy now and enjoy free delivery within Malaysia

Hepar-P 250mg Capsule
Hepar-P 500mg